Таргетная терапия плоскоклеточного рака головы и шеи


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Химиотерапия при лечении плоскоклеточного рака головы и шеи (ПРГШ) включена в современные схемы лечения местнораспространенных первичных опухолевых процессов, а также при развитии рецидива заболевания или появлении отдаленных метастазов. Но клиницисты не отрицают факта нарастания токсичности применяемых схем лечения и сравнительно низкой их эффективности. Применение таргетной терапии, в частности препарата цетуксимаб, расширило наши терапевтические возможности при лечении местнораспространенных опухолевых процессов и обеспечило высокую эффективность химиотерапии 1-й линии при рецидивах и отдаленных метастазах ПРГШ.

Полный текст

Доступ закрыт

Об авторах

И. С Романов

ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России

Email: drromanov@mail.ru
Москва

Список литературы

  1. GLOBOCAN 2012; http://globocan.iarc.fr/
  2. Cooper J.S, Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., Machtay M., Ensley J.F., Chao K.S., Schultz C.J., Lee N., Fu K.K.; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004;350:1937-44.
  3. Le Q.T, Giaccia A.J. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin. Cancer Res. 2003;9(12):4287-95.
  4. Penault-Llorca F. [Epidermal growth factor receptors: status evaluation methods and tumor expression]. Bull. Cancer. 2003;90:S186-91.
  5. Maurizi M., Almadori G., Ferrandina G., Distefano M., Romanini M.E., Cadoni G., Benedetti-Panici P., Paludetti G., Scambia G., Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer. 1996;74:1253-57.
  6. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., Drenning S.D., Tweardy D.J. Levels of TGF-β and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998;90(11):824-28.
  7. Psyrri A., Seiwert T.Y., Jimeno A. Molecular pathways in head and neck cancer. Am. Soc. Clin. Oncol. Educ. Book. 2013;246-55.
  8. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer. 2001;37(Suppl. 4):S3-8.
  9. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001;7;2958-70.
  10. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Sh in D. M., Cohen R.B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006;354(6):567-78.
  11. Bonner J.A., Harari P.M., Giralt J., Cohen R.B., Jones C.U., Sur R.K., Raben D., Baselga J., Spencer S.A., Zhu J., Youssoufian H., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-years survival data from a phase 3 randomised trial, and relation between cetuximab -induced rash and survival. Lancet Oncol. 2010;11(1):21-8.
  12. Ang K.K., Zhang Q.E., Rosenthal D.I., Nguyen-Tan P.F., Sherman E.J., Weber R.S., Galvin J.M., BonnerJ.A.,HarrisJ.,El-NaggarA.K.,GillisonM.L., Jordan R.C., Konski A.A., Thorstad W.L., Trotti A., Beitler J.J., Garden A.S., Spanos W.J., Yom S.S., Axelrod R.S. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 2014;32(27):294-50.
  13. Lefebvre J., Pointreau Y., Rolland F., Alfonsi M., Baudoux A., Sire C., de Raucourt D., Malard O., Degardin M., Tuchais C., Blot E., Rives M., Reyt E., Tourani J.M., Geoffrois L., Peyrade F., Guichard F., Chevalier D., Babin E., Lang P., Janot F., Calais G., Garaud P., Bardet E. Induction chemotherapy followed by either chemoradio-therapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J. Clin. Oncol. 2013;31(7):853-59.
  14. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008;359(11):116-1127.
  15. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., Knecht R., Amellal N., Schueler A., Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007;25(16):2171-77.
  16. Kies M.S., Garden A.S., Holsinger C., Papadimitrakopoulou V., ElNaggar A.K., Gillaspy K., LewinJ.,Lu C., VillalobosS.,Glisson B.S. Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 2006;24:285s. Abstract 5520.
  17. Mesia R., Henke M., Fortin A., Minn H., Yunes Ancona A.C., Cmelak A., Markowitz A.B., Hotte S.J., Singh S., Chan A.T., Merlano M.C., Skladowski K., Zhang A., Oliner K.S., VanderWalde A., Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-labelphase 2 trial. Lancet Oncol. 2015;16(2):208-20.
  18. Giralt J, Trigo J., Nuyts S., et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221-32.
  19. Vermorken J.B., Stöhlmacher-Williams J., Davidenko I., Licitra L., Winquist E., Villanueva C., Foa P., Ro ttey S., Skla do wski K.,TaharaM.,Pai V.R., Faivre S., Blajman C.R., Forastiere A.A., Stein B.N., Oliner K.S., Pan Z., Bach B.A. SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697-710.
  20. Machiels J.P., Subramanian S., Ruzsa A., Repassy G.,LifirenkoI.,FlygareA.,SorensenP.,Nielsen T., Lisby S., Clement P.M. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333-43.
  21. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., Vokes E.E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003;21(10):1980-87.
  22. Argiris A., Ghebremichael M., Gilbert J., Lee J.W., Sachidanandam K., Kolesar J.M., Burtness B., Forastiere A.A. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J. Clin. Oncol. 2013; 31(11):1405-14.
  23. Stewart J.S., Cohen E.E., Licitra L., Van Herpen C. M., Khorprasert C., Soulieres D., Vodvarka P., Rischin D., Garin A.M., Hirsch F.R., Varella-GarciaM.,Ghiorghiu S., Hargreaves L., Armour A., Speake G., Swaisland A., Vokes E.E. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 2009;27(11):1864-71.
  24. Harrington K., Berrier A., Robinson M., et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer. 2013;49(7):1609-18.
  25. Temam S., D'Cruz A., Jain M.M., D'Onofrio I., Manikhas G.M., Horvai G., Sun Y., Dietzsch S., Dubinsky P.,Holeckova P.,Mehanna H.,El-Hariry I., Franklin N., Biswas-Baldwin N., Legenne P., Wissel P.S., Netherway T., Santillana S., Bourhis J. Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 2014;23(Suppl., abstr. 6005):5s.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах